Amylyx Pharmaceuticals (AMLX) News Today $2.88 0.00 (0.00%) (As of 09/19/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are BuyingSeptember 17 at 10:05 AM | benzinga.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Purchases 40,000 SharesSeptember 17 at 4:52 AM | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO Acquires $101,200.00 in StockSeptember 17 at 4:50 AM | insidertrades.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmSeptember 16 at 11:42 AM | globenewswire.comShort Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 24.4%Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 1,490,000 shares, a decline of 24.4% from the August 15th total of 1,970,000 shares. Approximately 3.6% of the company's stock are short sold. Based on an average trading volume of 1,600,000 shares, the short-interest ratio is currently 0.9 days.September 15, 2024 | marketbeat.comBrokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $17.60September 15, 2024 | americanbankingnews.comAcadian Asset Management LLC Makes New Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Acadian Asset Management LLC purchased a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,211,617 shares of the companSeptember 14, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Hold" from AnalystsShares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been assigned an average rating of "Hold" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and two have given a buy raSeptember 12, 2024 | marketbeat.comDirector Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)September 9, 2024 | finance.yahoo.comAmylyx Pharmaceuticals: Management Ambitiously Navigates ChallengesSeptember 9, 2024 | seekingalpha.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. Purchases 100,000 SharesSeptember 6, 2024 | insidertrades.comDirector MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)September 6, 2024 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $220,000.00 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director George M. Milne, Jr. acquired 100,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now owns 858,571 shares in the company, valued at $1,888,856.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.September 5, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Significant Growth in Short InterestAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,970,000 shares, an increase of 5.9% from the July 31st total of 1,860,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.3% of the company's stock are short sold.September 2, 2024 | marketbeat.comCautious Optimism Amidst Uncertainty: Assessing Amylyx Pharmaceuticals’ Future ProspectsAugust 14, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Down 50.8% in JulyAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,860,000 shares, a decline of 50.8% from the July 15th total of 3,780,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the short-interest ratio is currently 1.1 days. Approximately 4.1% of the shares of the company are short sold.August 13, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | msn.comWe Think Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Easily Afford To Drive Business GrowthAugust 10, 2024 | finance.yahoo.comBuy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough DesignationAugust 9, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comAmylyx Pharmaceuticals GAAP EPS of -$1.07August 8, 2024 | msn.comAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finance.yahoo.comAmylyx Pharmaceuticals (AMLX) Scheduled to Post Quarterly Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports.August 6, 2024 | marketbeat.comShort Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Drops By 17.3%Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 3,780,000 shares, a decrease of 17.3% from the June 30th total of 4,570,000 shares. Currently, 8.2% of the shares of the stock are sold short. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 2.0 days.July 28, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Hold" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and two have assigned a buy rJuly 24, 2024 | marketbeat.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmJuly 18, 2024 | prnewswire.comAmylyx Pharmaceuticals (NASDAQ:AMLX) PT Raised to $4.00 at The Goldman Sachs GroupThe Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Friday.July 12, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Down 36.6% in JuneAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 4,570,000 shares, a drop of 36.6% from the June 15th total of 7,210,000 shares. Currently, 9.9% of the company's stock are sold short. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is currently 2.3 days.July 12, 2024 | marketbeat.comWhy Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?July 10, 2024 | benzinga.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday.July 10, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Hold" from BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. TheJune 29, 2024 | marketbeat.comAmylyx to buy bankrupt Eiger's experimental drug to treat low blood sugarJune 21, 2024 | reuters.comShort Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 5.3%Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 7,570,000 shares, a decrease of 5.3% from the May 15th total of 7,990,000 shares. Approximately 16.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,370,000 shares, the short-interest ratio is currently 3.2 days.June 18, 2024 | marketbeat.comPerceptive Advisors LLC Has $27.51 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Perceptive Advisors LLC lessened its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 30.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,869,125 shares of the company's stock after selling 819,June 16, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Avidity Partners Management LPAvidity Partners Management LP lessened its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 96.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 64,501 shares of the company's stock after selling 1,692,43June 11, 2024 | marketbeat.comAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 4, 2024 | businesswire.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Hold" by AnalystsShares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given an average recommendation of "Hold" by the eight research firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating onJune 4, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Decrease in Short InterestAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 7,990,000 shares, a drop of 6.1% from the April 30th total of 8,510,000 shares. Based on an average daily trading volume, of 3,350,000 shares, the short-interest ratio is presently 2.4 days. Approximately 17.4% of the shares of the company are short sold.June 2, 2024 | marketbeat.comFranklin Resources Inc. Purchases 707,134 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Franklin Resources Inc. raised its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 114.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,325,001 shares of the company's stock after acquiring an additional 707,May 28, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 10,455 SharesMay 17, 2024 | insidertrades.comAmylyx Pharmaceuticals (NASDAQ:AMLX) PT Lowered to $3.00Mizuho reduced their price target on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday.May 14, 2024 | marketbeat.comBank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amylyx Pharmaceuticals on Positive ALS and Wolfram Syndrome TrialsMay 10, 2024 | markets.businessinsider.comBreaking Down Amylyx Pharma: 9 Analysts Share Their ViewsMay 10, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports Q1 2024 Financial ResultsMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings ResultsAmylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. The firm had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same period in the previous year, the company earned $0.02 earnings per share.May 10, 2024 | marketbeat.comAmylyx Pharmaceuticals' (AMLX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a report on Friday.May 10, 2024 | marketbeat.comAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceMay 8, 2024 | businesswire.com Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Why You Should NOT Trade This Market (Ad)You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars... Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go AMLX Media Mentions By Week AMLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.830.44▲Average Medical News Sentiment AMLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼86▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mesoblast News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today ProKidney News Today Replimune Group News Today Scholar Rock News Today Humacyte News Today Corbus Pharmaceuticals News Today Annexon News Today Exscientia News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.